GlassScriptPhysician profile
Ashima Bahl
NPI 1477672228
$226,176.97
in general payments reported to CMS, 2019-2025
59 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75K · 2022: $91K · 2023: $37K · 2024: $9,323 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $13K · Honoraria: $7,785 · Travel and Lodging: $7,674 · Consulting Fee: $6,211 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,438.75 |
| Food and Beverage | $12,792.41 |
| Honoraria | $7,785.00 |
| Travel and Lodging | $7,673.82 |
| Consulting Fee | $6,211.00 |
| Education | $225.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $112,726.56 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $29,731.90 | 2021 | |
| Lilly USA, LLC | $17,080.05 | 2021-2025 | Emgality, Reyvow, Amyvid |
| Amgen INC. | $14,081.83 | 2021-2024 | Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $10,535.72 | 2022 | |
| Lundbeck LLC | $10,452.20 | 2021-2025 | Vyepti, Rexulti |
| Axsome Therapeutics, INC. | $7,486.64 | 2025 | Symbravo, Sunosi |
| Impel Pharmaceuticals INC. | $5,296.16 | 2023 | Trudhesa |
| Impel Pharmaceuticals LLC | $3,898.34 | 2025 | Trudhesa, Trudhesa |
| Teva Pharmaceuticals USA, INC. | $3,451.47 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Allergan, INC. | $1,625.64 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $1,151.93 | 2021-2025 | Epidiolex |
| Pfizer INC. | $950.38 | 2023-2025 | |
| Ucb, INC. | $799.47 | 2021-2025 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $759.45 | 2021-2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashima Bahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.